Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 10/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 10/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.50 |
| ▸ | STING1 | Q86WV6 | 6/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207334 | 0.87 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL1363426 | 0.87 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL1362756 | 0.87 | PDE4A (0.55) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL1362044 | 0.86 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL3223787 | 0.85 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL3220715 | 0.85 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL1363150 | 0.82 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL15189819 | 0.82 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL1364020 | 0.80 | UMPS (0.48) | PDE4APDE4BPDE4CPDE4DSTING1 | |
| SCHEMBL1363178 | 0.80 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DSTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931691-B1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | UNIV HEALTH NETWORK (CA) | 2013-08-21 | — | — | EP | claimed |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | claimed |
| WO-2008083465-A1 | PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS | UNIVERSITY HEALTH NETWORK (CA) | 2008-07-17 | — | — | WO | claimed |
| EP-1931691-B1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | UNIV HEALTH NETWORK (CA) | 2013-08-21 | — | — | EP | disclosed |
| US-8067391-B2 | ODCase inhibitors for the treatment of malaria | UNIVERSITY HEALTH NETWORK (CA) | 2011-11-29 | — | — | US | disclosed |
| US-20100087388-A1 | ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS | KOTRA LAKSHMI P | 2010-04-08 | — | — | US | disclosed |
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | UNIVERSITY HEALTH NETWORK (CA) | 2010-03-04 | — | — | US | disclosed |
| WO-2008083465-A1 | PYRIMIDINE DERIVATIVES AS ANTICANCER AGENTS | UNIVERSITY HEALTH NETWORK (CA) | 2008-07-17 | — | — | WO | disclosed |
| EP-1931691-A1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | University Health Network (CA) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007038860-A2 | ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS | UNIVERSITY HEALTH NETWORK (CA) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007038859-A1 | ODCASE INHIBITORS FOR THE TREATMENT OF MALARIA | UNIVERSITY HEALTH NETWORK (CA) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056468-A1 | Pyrimidine Derivatives As Anticancer Agents | DPYD, TYMP, TYMS | PDE4A 2919/4885PDE4B 2756/4885PDE4C 3387/4885 |
| US-20100087388-A1 | ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS | ITPA, DUT, MAOA | PDE4A 565/4885PDE4B 623/4885PDE4C 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.